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Abstract 
Background: Familial hypercholesterolemia (FH) is a genetic disorder that result in abnormally high low‑density 
lipoprotein cholesterol levels, markedly increased risk of coronary heart disease (CHD) and tendon xanthomas (TX). 
However, the clinical expression is highly variable. TX are present in other metabolic diseases that associate increased 
sterol concentration. If non‑cholesterol sterols are involved in the development of TX in FH has not been analyzed.
Methods: Clinical and biochemical characteristics, non‑cholesterol sterols concentrations and Aquilles tendon 
thickness were determined in subjects with genetic FH with (n = 63) and without (n = 40) TX. Student‑t test o 
Mann–Whitney test were used accordingly. Categorical variables were compared using a Chi square test. ANOVA and 
Kruskal–Wallis tests were performed to multiple independent variables comparison. Post hoc adjusted comparisons 
were performed with Bonferroni correction when applicable. Correlations of parameters in selected groups were 
calculated applying the non‑parametric Spearman correlation procedure. To identify variables associated with Achilles 
tendon thickness changes, multiple linear regression were applied.
Results: Patients with TX presented higher concentrations of non‑cholesterol sterols in plasma than patients 
without xanthomas (P = 0.006 and 0.034, respectively). Furthermore, there was a significant association between 
5α‑cholestanol, β‑sitosterol, desmosterol, 24S‑hydroxycholesterol and 27‑hydroxycholesterol concentrations and 
Achilles tendon thickness (p = 0.002, 0.012, 0.020, 0.045 and 0.040, respectively).
Conclusions: Our results indicate that non‑cholesterol sterol concentrations are associated with the presence of TX. 
Since cholesterol and non‑cholesterol sterols are present in the same lipoproteins, further studies would be needed 
to elucidate their potential role in the development of TX.
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Background
Familial hypercholesterolemia (FH), among the most 
common inherited metabolic disorders, is due to a 
group of genetic disorders that result in abnormally high 
low-density lipoprotein (LDL) cholesterol levels that 
cause atherosclerotic plaque deposition in arteries and a 
markedly increased risk of coronary heart disease (CHD) 
at a young age [1, 2]. FH has an autosomal codominant 
inheritance, with homozygotes having twice the LDL 
cholesterol levels of heterozygotes [1, 2]. The frequency 
of the heterozygous FH (HeFH) state has traditionally 
been estimated at 1 in 500 and of the homozygous FH 
(HoFH) state at 1 in 1,000,000, although recent popula-
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250 [3]. In HeFH patients, the clinical expression is highly 
variable in terms of the severity of hypercholesterolemia, 
the presence of tendon xanthomas (TX), and the age of 
onset and severity of CHD, even in subjects sharing the 
same LDLR gene defect [4]. Patients with FH predomi-
nantly have an excess of CHD rather than cerebral or 
peripheral arterial disease. The risk of premature CHD 
is elevated to about 20-fold in HeFH in comparison with 
the general population, with the highest risk being noted 
in young untreated men. HoFH typically develop CHD 
by the second decade of life, but CHD deaths in the first 
decade of life have been also reported [5].
TX are lipid deposits within certain tendons, mainly 
Achilles and extensors of the hands, that produce diffuse 
and/or focal thickening and predispose to inflammation, 
occasionally causing pain and impairment of function [6]. 
TX in the presence of severe hypercholesterolemia with 
autosomal dominant transmission is highly specific of 
FH [2], and a mutation in one LDL receptor-related gene 
is commonly found in this scenario [7]. HoFH typically 
develops TX in the first decade of life, while TXs begin to 
appear after the third decade of life in 20–50% of affected 
HeFH [2]. It is unknown why some HeFH subjects 
develop TX and others do not, even sharing the same 
pathogenic LDLR mutation [4], and it may be related to 
interindividual variability in the inflammatory response 
of macrophages to oxidized LDL particles [8].
The presence of TX has important clinical implications, 
because it is a major criterion for the clinical diagnosis of 
HoFH [9] and HeFH [3], and more importantly, subjects 
with TX associate higher LDL cholesterol, more intense 
subclinical atherosclerosis and higher risk of CHD and, 
probably, deserve a more intense lipid lowering therapy 
[3, 10].
Macrophage-derived foam cells due to intracellular 
accumulation of cholesterol, extracellular cholesterol 
deposits and connective tissue are the main components 
of TX [11]. Hence, pathological characteristics of TX 
are similar to atherosclerotic vascular lesions, both situ-
ations being produced by an accumulation of intra and 
extracellular cholesterol and an inflammatory reaction 
surrounded by fibrosis tissue. Furthermore, major risk 
factors for the development of CHD are also associated 
with the presence of TX, including age, male gender or 
high LDL cholesterol [12]. These results suggest that xan-
thomas and coronary atherosclerosis may share etiology, 
explaining the association between TX and CHD in FH.
TXs are also present in other sterol metabolism disor-
ders, such as sitosterolemia and cerebrotendinous xan-
thomatosis. Sitosterolemia is characterized by elevated 
phytosterol concentrations (β-sitosterol, campesterol…) 
and cerebrotendinous xanthomatosis by 27-hydroxycho-
lesterol deficiency and accumulation of 5α-cholestanol 
[13, 14]. In both diseases, TX are the result of non-cho-
lesterol sterols deposition rather than cholesterol, and, in 
both cases, TX can develop in absence of hypercholes-
terolemia, indicating that an increased exposure to non-
cholesterol sterols, even at a plasma concentration lower 
than cholesterol, can induce sterol accumulation within 
macrophages [13, 14]. Considering than non-cholesterol 
sterol concentration is elevated in FH although with large 
interindividual variability [15], we hypothesized that the 
presence of TX in HeFH could be favored by elevated 
non-cholesterol sterol concentrations in plasma. If this is 
the case, then elevated non-cholesterol sterol concentra-
tions could be involved in the production of TX in FH.
Methods
Study population
Hypercholesterolemic subjects from the Lipid Clinic at 
Hospital Universitario Miguel Servet, Zaragoza, Spain 
were selected. They were unrelated adults 18–79  years 
of age with the clinical and genetic diagnosis of FH 
(n = 103). FH was defined in presence of LDL cholesterol 
above the 95th percentile of the Spanish population [16], 
triglycerides below 200  mg/dl, familial presentation (at 
least one first-degree relative with the same phenotype) 
and heterozygous for a functional mutation in LDLR, 
APOB, PCSK9 or APOE genes. Exclusion criteria: sec-
ondary causes of hypercholesterolemia including: severe 
obesity (body mass index (BMI)  >  35  kg/m2), poorly 
controlled type 2 diabetes (HbA1c  >  8%), renal disease 
with glomerular filtration rate < 30 ml/min and/or mac-
roalbuminuria, liver diseases (ALT > 3 times upper nor-
mal limit), hypothyroidism (TSH > 6 mIU/l), pregnancy, 
autoimmune diseases and protease inhibitors consump-
tion. Subjects disclosing APOE ε2/ε2 genotype were also 
excluded for this study. Subjects with previous CVD were 
excluded except if they were not on lipid-lowering drugs.
CVD risk factors assessment, personal and family his-
tory of CVD, consumption of drugs affecting intestinal 
or lipid metabolism and anthropometric measurements 
were performed in all participants. All subjects signed 
informed consent to a protocol previously approved by 
our local ethical committee (Comité Ético de Investi-
gación Clínica de Aragón, Zaragoza, Spain).
Tendon xanthomas measurements
TXs were measured in the Achilles tendons using high 
resolution sonography. Standardized equipment and 
operating procedures were used for Achilles tendon 
thickness measurements as previously described [17]. 
The variables of interest were mean and maximum Achil-
les tendon thickness, bilaterally. TX was defined when 
Achilles tendon maximum thickness was over 5.3 and 
5.7  mm in men  <  45 and  >  45  years, and over 4.8 and 
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4.9 mm in women < 50 and > 50 years, respectively. These 
thickness thresholds have demonstrated to be good dis-
criminators for the TX diagnosis in HeFH [17].
Clinical and laboratory parameters
Fasting blood for biochemical profiles was drawn after 
at least 5–6  weeks without hypolipidemic drug treat-
ment, plant sterols or fish oil supplements. Cholesterol 
and triglycerides were determined by standard enzymatic 
methods. High density lipoprotein (HDL) cholesterol 
was measured by a precipitation technique. Apolipopro-
tein (apo) A1, apo B, lipoprotein(a) (Lp(a)) and C-reac-
tive protein were determined by inmunonephelometry 
using IMMAGE-Immunochemistry System (Beckman 
Coulter).
DNA was isolated from EDTA blood samples following 
standard protocols. APOE sequencing was performed in 
all study subjects as previously described [18]. The screen-
ing for LDLR, APOB and PCSK9 mutations was carried 
out using Lipochip Platform (Progenika Biopharma S. A., 
Bilbao, Spain). The platform consists of two consecutive 
steps: the first one is the LIPOchip1 microarray analysis 
for the detection of the most frequent Spanish point muta-
tions in the LDLR gene and in the APOB exon 26, as well 
as CNVs in LDLR. When the LIPOchip1 microarray gives 
a negative result (no mutation is found), the LDLR, APOB 
(binding domain) and PCSK9 gene coding sequences, 
exon–intron boundaries, and short proximal intronic 
sequences were sequenced with a GS Junior system (Roche 
Diagnostics Corporation, Basel, Switzerland) [19].
Serum sterol determinations
Serum concentration of 5α-cholestanol, β-sitosterol, 
campesterol, stigmasterol, sitostanol, desmosterol, lanos-
terol, 24S-hydroxycholesterol, 27-hydroxycholesterol 
and 7α-hydroxy-4-cholesten-3-ona and cholesterol were 
quantified after 10  h of fasting. They were quantified 
using high performance liquid chromatography tandem 
mass spectrometry (HPLC–MS/MS) according to the 
method previously described [20], and were expressed 
as mg/dl as well as normalized to mg/dl of total choles-
terol. Briefly, 100 µl of serum were transferred to a screw-
capped vial and deuterium-labelled internal standard, 
(2H6) cholesterol-26,26,26,27,27,27, (7.9 mM), was added 
to determine non-cholesterol sterol concentrations. 
Another 100  µl of serum were transferred to a screw-
capped vial, deuterium-labelled internal standard, (2H7) 
cholesterol-25,26,26,26,27,27,27, was added to deter-
mine cholesterol. Alkaline hydrolysis was performed for 
20 min at 60 °C in an ultrasound bath and extracted twice 
with 3 ml of hexane. The extracts were loaded onto the 
SPE cartridge (1 mg, Discovery DSC-18, Supelco, Spain) 
which was preconditioned with 400  µl of methanol and 
gravity eluted. Sterols were desorbed with 1.4  ml of 
2-propanol by gravity and 40 µl of the final mixtures were 
injected into the HPLC–MS/MS system.
Statistical analysis
Statistical analysis was performed using SPSS soft-
ware version 15.0 (Chicago, Illinois, USA) using a sig-
nificance level of P values < 0.05. Data are expressed as 
mean  ±  standard deviation for continuous variables 
with normal distribution and medians (percentile 25–
percentile 75) for variables with a skewed distribution. 
Student t test o Mann–Whitney test were used accord-
ingly. Categorical variables were compared using a Chi 
square test. ANOVA and Kruskal–Wallis tests were per-
formed to multiple independent variables comparison. 
Post hoc adjusted comparisons were performed with 
Bonferroni correction when applicable. Correlations of 
parameters in selected groups were calculated applying 
the non-parametric Spearman correlation procedure. 
To identify variables associated with Achilles tendon 
thickness changes, we applied multiple linear regression 
with age, height and 5α-cholestanol, β-sitosterol, camp-
esterol, stigmasterol, sitostanol, desmosterol, lanosterol, 
24S-hydroxycholesterol, 27-hydroxycholesterol and 
7α-hydroxy-4-cholesten-3-ona as independent variables.
Results
Clinical and biochemical characteristics
The main clinical and biochemical characteristics of 103 
FH subjects without and with xanthomas are presented 
in Table 1. Both groups did not have statistically signifi-
cant differences in most of the clinical and biochemical 
characteristics. Corneal arcus was significantly higher in 
patients with xanthomas than in those patients without 
xanthomas (P  <  0.009). No differences in age, tobacco 
consumption, CVD, diabetes, hypertension neither other 
characteristics were found between patients without and 
with xanthomas.
Lipid profile, Achilles tendon thickness and serum 
non‑cholesterol sterols
The lipid profile and Achilles tendon thickness of FH 
without and with xanthomas is presented in Table  2. 
Patients with xanthomas had significantly higher values 
of total cholesterol, non-HDL cholesterol, LDL choles-
terol and apo B than patients without xanthomas. No 
differences in triglycerides, HDL cholesterol and apo A1 
were found between both studied groups of patients. As 
expected, the maximum and the mean Achilles tendon 
thickness were significantly higher in FH subjects with 
xanthomas than in those FH subjects without xanthomas.
Non-cholesterol sterols values are also presented in 
Table  2. 5α-cholestanol and β-sitosterol, cholesterol 
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absorption surrogate markers, were statistically sig-
nificant higher in FH subjects with xanthomas than in 
FH subjects without xanthomas (P  =  0.006 and 0.034, 
respectively). No differences in cholesterol synthesis sur-
rogate markers neither oxysterols were found between 
FH subjects with and without xanthomas.
Achilles tendon thickness association with serum 
non‑cholesterol sterols concentrations
Linear regression analysis showed a significant posi-
tive association of 5α-cholestanol and β-sitosterol 
with maximum and mean Achilles tendon thickness. 
5α-cholestanol and β-sitosterol concentration explained 
23.2 and 23.1% of the maximum Achilles tendon thick-
ness, and 20.3 and 20.4% of the mean Achilles tendon 
thickness variation, respectively (Table  3). Desmosterol 
concentration also showed a significant positive associa-
tion with the maximum and the mean Achilles tendon 
thickness. Desmosterol concentration determined 19.5% 
of maximum and 19.6% of mean Achilles tendon thick-
ness (Table  3). 24S-hydroxycholesterol and 27-hydroxy-
cholesterol concentrations also showed a significant 
positive association with the maximum and the mean 
Achilles tendon thickness. 24S-hydroxycholesterol 
concentration determined 18.3% of maximum Achil-
les tendon thickness and 27-hydroxycholesterol con-
centration determined 18.5% of maximum and 18.5% of 
mean Achilles tendon thickness (Table 3). The rest of the 
measured non-cholesterol sterols were not significantly 
associated to the maximum neither the mean Achil-
les tendon thickness. The positive associations between 
5α-cholestanol, β-sitosterol and desmosterol and the 
maximum and the mean Achilles tendon thickness are 
shown in the Fig. 1. However, the significant association 
of non-cholesterol sterols with Achilles tendon thickness 
disappeared when non-cholesterol sterols concentra-
tions were adjusted by total cholesterol and LDLc con-
centrations (Additional file 1: Tables S1, S2). There was a 
positive correlation between total cholesterol and LDLc 
levels and maximum and mean Achilles tendon thick-
ness  (RTC = 0.302; p = 0.003,  RLDLc = 0.304; p = 0.003 
and  RTC = 0.302; p = 0.001,  RLDLc = 0.336; p = 0.0001, 
respectively). 
Discussion
The mechanism of production of TX in FH is not known. 
Traditionally, it has been observed that the appearance 
of xanthomas is related to the appearance of classic car-
diovascular risk factors and to the concentration of LDL 
cholesterol [2]. However, these factors do not account 
for the majority of cases with xanthomas. Sometimes, 
xanthomas are clustered in families; therefore, it could 
be thought that the mutation responsible for hypercho-
lesterolemia would play a role in their development. 
Table 1 Clinical and biochemical characteristics of study subjects without or with tendon xanthomas
Numerical variables with normal distribution are expressed as mean ± standard deviation and those with skewed distribution are expressed as median [percentile 








Age, years 39.4 ± 13.2 40.7 ± 13.0 0.639
Men, n (%) 32 (50.8) 18 (45.0) 0.566
Current smokers, n (%) 19 (31.7) 7 (17.5) 0.286
Non‑smokers, n (%) 30 (50.0) 24 (60)
Former smokers, n (%) 11 (18.3) 9 (22.5)
Carotid plaque, n (%) 9 (15.5) 5 (13.2) 0.674
Diabetes, n (%) 2 (3.2) 1 (2.5) 0.843
Hypertension, n (%) 7 (11.1) 3 (7.5) 0.546
Body mass index, Kg/m2 24.2 ± 3.7 25.0 ± 3.4 0.251
Corneal arcus, n (%) 11 (17.5) 23 (41.0) 0.009
Lipoprotein(a), mg/dl 27.6 (12.4–45.5) 26.0 (11.2–51.6) 0.994
Glucose, mg/dl 87 (81–93) 86 (80–95) 0.935
C‑reactive protein, g/l 1.8 (0.5–3.4) 0.85 (0.52–2.1) 0.202
APOE genotype E3/3, n (%) 38 (60.3) 27 (69.2) 0.736
APOE genotype E3/2, n (%) 7 (11.1) 4 (10.3)
APOE genotype E3/4, n (%) 17 (27.0) 7 (17.9)
APOE genotype E2/4, n (%) 1 (1.6) 1 (2.6)
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However, studies performed in populations where a sin-
gle mutation is prevalent, such as the Canadians in Que-
bec region, show that although they share a mutation, 
they still maintain a huge variability in the presentation 
of xanthomas [4]. This would indicate that other genetic 
and/or environmental factors that are shared in families 
could play a role in the development of xanthomas.
The concentration of serum non-cholesterol sterols is 
highly variable and has an evident polygenic component, 
as we have recently been able to demonstrate in families 
with hypercholesterolemia [21]. This indicates that both 
the absorption and the synthesis of cholesterol have some 
genetic control and could be involved in the familial asso-
ciation of TX.
However, our hypothesis has not been fully confirmed 
in this study. Although non-cholesterol sterols, especially 
markers of intestinal absorption and hepatic synthesis, 
are elevated in subjects with xanthomas, this associa-
tion disappears when adjusted for total cholesterol con-
centration. Non-cholesterol sterols, like cholesterol, are 
transported in lipoproteins, especially within the LDL 
particles; therefore in the FH, where the number of LDL 
particles is very high, the transport of sterols is expected 
to be increased [22]. Hence, most authors recommend 
adjusting the values of non-cholesterol sterols by the con-
centration of total cholesterol [23]. Since cholesterol and 
non-cholesterol sterols are bound in the same lipoprotein 
particles, it is not possible in our study to differentiate 
the cholesterol-dependent effect of the sterol-depend-
ent effect. The fact that different diseases that associate 
increase in the sterol concentrations develop TX indi-
cates that non-cholesterol sterols by themselves, even in 
the absence of hypercholesterolemia, are able to promote 
TX [13, 14].
The associated inflammatory tissue in xanthoma is 
very similar to that of the atheroma plaque, predomi-
nantly lipid-laden macrophages, especially cholesterol 
esters [24]. The modified LDL particle captured by mac-
rophages from both the wall and the xanthomas captures 
both cholesterol and sterols. However, the capacity of 
esterification by macrophages is much higher for cho-
lesterol than for sterols that accumulate as free sterols 
in the lesions [25]. If this differential mechanism is the 
responsible of the appearance of xanthomas is not well 
known, but what has been well demonstrated is that the 
inflammatory reaction induced by LDL is different from 
Table 2 Lipid profile, non-cholesterol sterols and Achilles tendon thickness of subjects without or with xanthomas
Values are mean ± SD or median (interquartile range). P refers to differences calculated by Student’s t test for data normally distributed and Mann–Whitney U test for 
skewed data







Total cholesterol, mg/dl 308.8 ± 48.2 354.9 ± 63.1 < 0.001
Triglycerides, mg/dl 93 (66–149) 98 (65–175) 0.707
HDL cholesterol, mg/dl 51.9 ± 15.7 54.9 ± 16.4 0.369
Non‑HDL cholesterol, mg/dl 256.8 ± 47.3 300.1 ± 62.0 < 0.001
LDL cholesterol, mg/dl 235.4 ± 51.6 274 ± 55.0 0.001
Apolipoprotein A1, mg/dl 148.6 ± 34.8 143.4 ± 31.8 0.450
Apolipoprotein B, mg/dl 172.5 ± 31.4 191.4 ± 48.1 0.019
Maximum Achilles tendon thickness, mm 4.70 (4.43–4.95) 5.71 (5.30–6.88) < 0.001
Mean Achilles tendon thickness, mm 4.51 (4.16–4.73) 5.49 (5.05–6.63) < 0.001
Cholesterol HPLC–MS/MS, mg/dl 314.6 ± 52.1 351.4 ± 73.1 0.004
5α‑cholestanol, mg/dl 0.665 ± 0.269 0.843 ± 0.375 0.006
β‑sitosterol, mg/dl 0.602 ± 0.319 0.767 ± 0.462 0.034
Campesterol, mg/dl 0.329 ± 0.173 0.384 ± 0.230 0.176
Stigmasterol, mg/dl 0.0462 ± 0.0296 0.0528 ± 0.0287 0.269
Sitostanol, mg/dl 0.0217 (0.0093–0.0551) 0.0338 (0.0119–0.0565) 0.614
Desmosterol, mg/dl 0.773 ± 0.345 0.896 ± 0.430 0.109
Lanosterol, mg/dl 0.820 ± 0.383 0.896 ± 0.430 0.566
24S‑hydroxycholesterol, mg/dl 0.0100 ± 0.0042 0.0115 ± 0.0061 0.142
27‑hydroxycholesterol, mg/dl 0.0163 (0.0117–0.0210) 0.0167 (0.0123–0.0270) 0.161
7α‑hydroxy‑4‑cholesten‑3‑ona, mg/dl × 10 0.0370 (0.0253–0.0542) 0.0358 (0.0242–0.0511) 0.735
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some subjects to others [26]. In a previous study, we had 
demonstrated that macrophages from FH subjects with 
TX stimulated with oxLDL showed an overexpression of 
chemokine IL-8 and CXCL3 genes and produced higher 
IL-8 protein levels than macrophages from FH subjects 
without TX. However, we could not demonstrate if 
the observed inflammatory effect was LDL cholesterol 
dependent [27, 28].
The use of plant sterols in the treatment of hypercho-
lesterolemia is a well-accepted cholesterol reduction pro-
cedure that has also been proposed as a lipid-lowering 
treatment in HeHF [29]. However, as far as we know, the 
use of plant sterols in familial hypercholesterolemia has 
not been associated with the development of xanthomas. 
The importance of the sterol 27-hydroxylase-mediated 
mechanism in the xanthoma development is illustrated 
by the fact that patients who lack this enzyme develop 
xanthomas and premature atherosclerosis in spite of 
normal levels of circulating  cholesterol [30]. Patients 
with the inherited disease cerebrotendinous xanthoma-
tosis lack the enzyme sterol 27-hydroxylase (CYP27A1). 
In humans without this enzyme defect, 27-hydroxy-
cholesterol accumulates in atherosclerotic lesions. Fur-
thermore, the enzyme sterol 27-hydroxylase has been 
identified in tendocytes and macrophages and induces 
conversion of cholesterol to the more polar metabolite 
27-hydroxycholesterol, which can be eliminated from the 
cells more effectively [31].
Our study has several limitations. First, we do not know 
the concentration of non-cholesterol sterols in Achil-
les tendon, we have only measured them in serum and it 
would have been interesting to know the real concentra-
tion of sterols in xanthomas instead of in blood. Secondly, 
the lipid-lowering treatment modifies the development of 
xanthomas and the subjects of our study, although they 
were untreated at the time of analysis, most of them had 
variable time with statins that may have altered tendon 
thickness. Finally, the definition of TX is arbitrary and 
based on a continuous variable, such as tendon thick-
ness; if other definition of TX could yield different results 
would be possible, although seems improbable because 
those subjects in the highest quartile of Achilles ten-
don thickness did not significantly differ from the rest of 
quartiles.
Conclusion
HeFH subjects with TX present higher concentrations of 
non-cholesterol sterols in serum than HeFH subjects without 
TX. Furthermore, there is a significant association between 
5α-cholestanol and β-sitosterol serum concentration and 
Table 3 Achilles tendon thickness association with serum non-cholesterol sterols concentrations
The linear regression analysis was adjusted by age and height
FH
n = 103
Achilles tendon thickness B [95% CI] p R2
5α‑cholestanol, mg/Dl Maximum − 0.033 − 0.054, − 0.013 0.002 23.2
Mean − 0.035 − 0.057, − 0.012 0.003 23.1
β‑sitosterol, mg/dl Maximum − 0.022 − 0.040, − 0.005 0.012 20.3
Mean − 0.024 − 0.232, − 2.489 0.015 20.4
Campesterol, mg/dl Maximum − 0.031 − 0.067, 0.004 0.081 18.6
Mean − 0.033 − 0.071, 0.005 0.088 18.9
Stigmasterol, mg/dl Maximum − 0.172 − 0.412, 0.068 0.157 16.5
Mean − 0.191 − 0.449, 0.066 0.144 17.0
Sitostanol, mg/dl Maximum 0.037 − 0.197, 0.270 0.756 14.7
Mean 0.019 − 0.232, 0.270 0.881 15.1
Desmosterol, mg/dl Maximum − 0.022 − 0.041, − 0.004 0.020 19.5
Mean − 0.023 − 0.043, − 0.003 0.025 19.6
Lanosterol, mg/dl Maximum − 0.100 − 0.444, 0.245 0.567 14.9
Mean − 0.110 − 0.480, 0.260 0.556 15.4
24S‑hydroxycholesterol, mg/dl Maximum − 1.420 − 2.810, − 0.030 0.045 18.3
Mean − 1.428 − 2.926, 0.070 0.061 18.3
27‑hydroxycholesterol, mg/dl Maximum − 0.820 − 1.600, − 0.04 0.040 18.5
Mean − 0.858 − 1.697, − 0.018 0.045 18.7
7α‑hydroxy‑4‑cholesten‑3‑ona, mg/dl × 10 Maximum 0.339 − 1.526, 2.203 0.719 14.7
Mean 0.425 − 1.579, 2.428 0.675 15.2
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Fig. 1 Association between serum non‑cholesterol sterols and the maximum and the mean Achilles tendon thickness in subjects with familial 
hypercholesteroemia
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Achilles tendon thickness. Our results indicate that non-cho-
lesterol sterol concentrations are associated with the pres-
ence of xanthomas in familial hypercholesterolemia. Since 
cholesterol and non-cholesterol sterols are present in the 
same lipoprotein particles further studies would be needed 
to elucidate their role in the development of TX.
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